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To assess the impact of COVID-19 restrictions on cystic fibrosis (CF) pulmonary exacerbations (PEx) we performed a retro-
spective review of PEx events at our CF Center and compared the rate of PEx in 2019 vs 2020. Restrictions on social interaction
due to the COVID-19 pandemic were associated with a lower rate of PEx at our pediatric CF Center, suggesting that these
restrictions also reduced exposure to other respiratory viral infection in children with CF.
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Abstract:
To assess the impact of COVID-19 restrictions on cystic fibrosis (CF) pulmonary exacerbations (PEx) we
performed a retrospective review of PEx events at our CF Center and compared the rate of PEx in 2019
vs 2020. Restrictions on social interaction due to the COVID-19 pandemic were associated with a lower
rate of PEx at our pediatric CF Center, suggesting that these restrictions also reduced exposure to other
respiratory viral infection in children with CF.
To The Editor:
The COVID-19 pandemic resulted in widespread restrictions on social interactions and lockdowns in many
areas of the world [1]. The impact of these measures on cystic fibrosis (CF) pulmonary exacerbations (PEx)
has not been described. Respiratory viral infections are a common trigger for PEx [2, 3], and COVID-19
restrictions might lead to fewer PEx by reducing exposure to viruses in general, not just SARS-CoV2. To test
the hypothesis that the COVID-19 lockdown would be associated with a lower PEx incidence we compared
PEx data at our CF Center from the time with the most stringent restrictions in Indiana to the same time
interval in 2019.
We identified PEx events by performing a retrospective chart review of children with CF followed at the CF
Center at Riley Hospital for Children. We limited the age range to 2-11 years to avoid any potential con-
founding by elexacaftor/tezacaftor/ivacaftor therapy [4, 5]. We collected data from two time intervals in both
2019 and 2020: January 1 to March 15 (which corresponded to the months prior to the COVID-19 detection
in Indiana) and March 16 to May 15 (which corresponded with the months of peak COVID-19 incidence
in 2020). PEx was determined by the treating clinician based on changes in signs, symptoms, and/or lung
function. Every PEx event was analyzed during these timeframes, and data collected included demographics,
height and weight, lung function, microbiology, location of encounter, and antibiotic treatment. Data were
analyzed using descriptive statistics and generalized linear models where data had repeated measures. This
project was reviewed and approved by our local institutional review board prior to data collection.
The number and location of PEx events during the time intervals studies are shown in the Table. The number
of PEx events were significantly decreased in both time intervals in 2020 compared to 2019, although the
decline was even greater from March 16 to May 15. The location of patients’ PEx events also differed between
2019 and 2020, with a significantly lower percentage of PEx occurring through in-person clinic visits and a
much larger percentage occurring through phone encounters. The number of patients (80 in 2019 and 78
in 2020) and their clinical characteristics, such as sex, genotype, respiratory culture history, baseline lung
function, and nutritional indices were similar for both years, suggesting that our observations were not due
to an overall improvement in the health of our patients. However, whereas 100% of clinic visits in 2019 and
from January 1-March 16 2020 were in-person, only 16% of visits during the March 16-May 15 2020 time
interval were in-person.
Our analysis shows that COVID-19 restrictions were associated with decreased PEx events and a shift
towards PEx diagnosis through phone encounters rather than in-person visits. We speculate that this may
have occurred due to reduced exposure to respiratory viral infections in general. It is also possible that
because our patients and their parents were both at home more, there was improved adherence. We also
observed a reduction in PEx rate prior to March 16, which may reflect the fact that patients were already
engaging in a degree of self-isolation prior to the statewide lockdown. The decrease in in-person PEx events
reflects the increased use of telehealth at the height of the COVID-19 pandemic in Indiana. Limitations of
our analysis include the retrospective study design and the fact that we only analyzed data from a single
CF Center.
In summary, restrictions on social interaction due to the COVID-19 pandemic were associated with a lower
rate of PEx at our pediatric CF Center. These results are consistent with other studies demonstrating

















































































































































burden of CF lung disease should severe lockdowns due to COVID-19 occur again in their region.
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